- Home
- ACRS vs SWKH Comparison
ACRS vs SWKH Comparison
Compare ACRS & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- SWKH
- Stock Information
- Founded
- ACRS 2012
- SWKH 1996
- Country
- ACRS United States
- SWKH United States
- Employees
- ACRS N/A
- SWKH N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- SWKH Diversified Financial Services
- Sector
- ACRS Health Care
- SWKH Finance
- Exchange
- ACRS Nasdaq
- SWKH Nasdaq
- Market Cap
- ACRS 170.9M
- SWKH N/A
- IPO Year
- ACRS 2015
- SWKH 1999
- Fundamental
- Price
- ACRS $1.53
- SWKH $17.39
- Analyst Decision
- ACRS Strong Buy
- SWKH
- Analyst Count
- ACRS 7
- SWKH 0
- Target Price
- ACRS $11.67
- SWKH N/A
- AVG Volume (30 Days)
- ACRS 1.2M
- SWKH 8.6K
- Earning Date
- ACRS 05-06-2025
- SWKH 03-19-2025
- Dividend Yield
- ACRS N/A
- SWKH N/A
- EPS Growth
- ACRS N/A
- SWKH N/A
- EPS
- ACRS N/A
- SWKH 1.08
- Revenue
- ACRS $18,720,000.00
- SWKH $27,546,000.00
- Revenue This Year
- ACRS N/A
- SWKH $52.93
- Revenue Next Year
- ACRS N/A
- SWKH N/A
- P/E Ratio
- ACRS N/A
- SWKH $16.10
- Revenue Growth
- ACRS N/A
- SWKH N/A
- 52 Week Low
- ACRS $0.95
- SWKH $15.14
- 52 Week High
- ACRS $5.17
- SWKH $18.09
- Technical
- Relative Strength Index (RSI)
- ACRS 28.64
- SWKH 59.34
- Support Level
- ACRS $1.57
- SWKH $16.85
- Resistance Level
- ACRS $1.78
- SWKH $16.40
- Average True Range (ATR)
- ACRS 0.10
- SWKH 0.42
- MACD
- ACRS 0.02
- SWKH 0.11
- Stochastic Oscillator
- ACRS 17.74
- SWKH 73.42
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.